Previous 10 | Next 10 |
Summary This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total retu...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...
Amicus Therapeutics' AT-GAA approval in Pompe Disease has been pushed back by 3 months. However, the stock seems buoyant enough. I will continue holding, taking profits where I can. In my previous coverage in May, I wrote the following desultory text: Amicus Th...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q1-2022 13F filings the consensus holdings were updated, 10 stocks were removed and 8 added from the univ...
Amicus Therapeutics, Inc. (FOLD) Q2 2022 Earnings Conference Call August 04, 2022, 08:30 ET Company Participants Andrew Faughnan - Senior Director, IR Bradley Campbell - CEO, President & Director Sebastien Martel - Chief Business Officer Jeffrey Castelli ...
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Amicus Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Amicus Therapeutics press release ( NASDAQ: FOLD ): Q2 GAAP EPS of -$0.21 beats by $0.01 . Revenue of $80.7M (+4.3% Y/Y) misses by $5.18M . For the full-year 2022, the company anticipates total Galafold revenue of $350 million to $365 million at constant exchan...
1H22 Galafold ® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7% On-Track to Deliver Full-Year Double-Digit Revenue Growth of 15-20% at Constant Exchange Rat...
Amicus Therapeutics ( NASDAQ: FOLD ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.22 (-15.8% Y/Y) and the consensus Revenue Estimate is $85.88M (+11.0% Y/Y). Over the last 1 year, FOLD has...
PHILADELPHIA, July 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2022. I...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K....